Clinical trials: Unresectable Dedifferentiated Liposarcoma

Dedifferentiated Liposarcoma

Selinexor in Advanced Liposarcoma

• Completed
• Age: 12 years and older
• Phase 2/3
• Results posted

This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma.

Trial name

SEAL (NCT02606461)

Testing

Selinexor

Where

71 sites in United States, Belgium and 8 more

Volunteers

342 people

Sponsor

Karyopharm Therapeutics Inc